NAM
AGRX

Nexpoint Asset Management’s Agile Therapeutics AGRX Stock Holding History

Nexpoint Asset Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13
Closed -$52K – 210
2021
Q1 		$52K Hold
13
– – 0.01% 161
2020
Q4 		$72K Hold
13
– – 0.02% 140
2020
Q3 		$76K Hold
13
– – 0.02% 153
2020
Q2 		$70K Hold
13
– – 0.02% 185
2020
Q1 		$47K Sell
13
-17
-57% -$97.6K 0.01% 206
2019
Q4 		$150K Sell
30
-20
-40% -$69.8K 0.01% 267
2019
Q3 		$119K Buy
+50
New +$123K 0.01% 311

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nexpoint Asset Management's AGRX Position: Q2 2021 in Review

Nexpoint Asset Management sold out of Agile Therapeutics (AGRX) in Q2 2021, closing a stake of 13 shares — an estimated $52K sold.

Nexpoint Asset Management first reported a position in AGRX in Q3 2019 and held it in 7 quarters. The position peaked at $150K in Q4 2019. 64 funds tracked by Wall St. Rank hold AGRX as of Q2 2021.

  • Nexpoint Asset Management reported no remaining Agile Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Nexpoint Asset Management sold 13 Agile Therapeutics shares in Q2 2021, an estimated $52K.
  • Nexpoint Asset Management first reported a position in Agile Therapeutics in Q3 2019 and held it in 7 quarters.
  • Nexpoint Asset Management's Agile Therapeutics position peaked at $150K in Q4 2019.
  • 64 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2021.

Based on Nexpoint Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.